PCSK9 Inhibition and Risk of Diabetes: Should We Worry?

PURPOSE OF REVIEW: Since the clinical benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors occurs in a setting of reducing low-density lipoprotein-cholesterol (LDL-C) to unprecedentedly low levels, it becomes of interest to investigate possible adverse effects pertaining to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Carugo, Stefano, Sirtori, Cesare R., Corsini, Alberto, Tokgozoglu, Lale, Ruscica, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Cardiometabolic Disease and Treatment (R. Santos, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750910/
https://www.ncbi.nlm.nih.gov/pubmed/36383291
http://dx.doi.org/10.1007/s11883-022-01074-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750910/
https://www.ncbi.nlm.nih.gov/pubmed/36383291
http://dx.doi.org/10.1007/s11883-022-01074-y

Ejemplares similares